Previous 10 | Next 10 |
home / stock / acog:cc / acog:cc news
Not for distribution in the United States or to U.S. newswire services Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders...
Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today repor...
Not for distribution in the United States or to U.S. newswire services Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“ Alpha Cognition ”, or the “ Company ”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerati...
Not for distribution in the United States or to U.S. newswire services Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“ Alpha Cognition ”, or the “ Company ”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerati...
Not for distribution in the United States or to U.S. newswire services Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“ Alpha Cognition ”, or the “ Company ”), a biopharmaceutical company committed to developing novel therapies with the potential ...
Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announced tod...
Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced...
Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VANCOUVER, British Columbia, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (“Alpha” or the “Company”) (TSXV:ACOG) (OTCQB: ACOGF), a biopharmaceutical company committ...
IIROC Trading Resumption - ACOG Canada NewsWire VANCOUVER, BC , Nov. 18, 2022 /CNW/ - Trading resumes in: Company: Alpha Cognition Inc. TSX-Venture Symbol: ACOG All Issues: Yes Resumption (ET): 9:30 AM IIROC can make a decision to impo...
News, Short Squeeze, Breakout and More Instantly...
Alpha Cognition Inc. Company Name:
ACOG:CC Stock Symbol:
TSXVC Market:
Alpha Cognition Inc. Website:
The Second Oral Therapy Approved This Decade, ZUNVEYL’s Dual MOA Was Designed to Eliminate Drug Absorption in the Gastrointestinal (GI) Tract, Potentially Addressing Certain Tolerability Issues with Leading Alzheimer’s Disease (AD) Medications, Combined with a Long-Term Efficacy Pro...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...